Armis Named Leader in GigaOm Radar Report for Operational Technology (OT) Security
Armis, the leading asset visibility and security company, today announced that it has been named a leader in the GigaOm Radar Report for Operational Technology (OT) Security.
“We’re proud to be recognized by GigaOm as a leader in operational technology security,” said Nadir Izrael, CTO and Co-founder, Armis. “It’s critical to secure the hardware and software systems that control physical devices and the industrial processes that our society depends on. Our mission is to ensure the availability, reliability and safety of these industrial control systems by mitigating cybersecurity risks that could otherwise lead to system failures, operational disruptions or physical damages.”
Within the GigaOm Radar for OT Security, Armis is:
- positioned in the Leaders ring, recognized for being a highly scalable platform and for the solution's strong vulnerability management features, practical AI and dynamic segmentation.
- housed in the Innovation/Platform Play quadrant. The Innovation positioning highlights technical innovation while the Platform Play displays a broader platform focus and commitment to a comprehensive feature set.
- recognized as a Fast Mover when evaluating strategy and pace of innovation in this forward-looking assessment plotting the current projected positioning of each vendor over a 12- to 18-month window.
“Of all the vendors we looked at, Armis provided the fastest time to value and the widest coverage. Because it’s cloud-based, Armis is also simple to manage. All these factors made it easy to choose Armis, frankly,” said Mike Towers, Chief Security and Trust Officer, Takeda Pharmaceuticals. “Thanks to Armis, we’ve already uncovered a series of potential cyber risks. Without the Armis deployment, we never would have known they existed. It has already paid for itself.”
Armis is rated exceptional in the report for its:
- SaaS solution which serves large enterprises and manufacturers
- AI technologies for threat detection and rendezvous capabilities which GigaOm considered differentiating and critical in this sector
- product evaluation metrics, specifically scalability and compliance.
Additionally, Armis was recognized as the only OT vendor with FedRAMP Moderate ATO, ISO 27001, ISO 28018 Best Practices and SOC 2 Type II certifications.
“A key differentiator for Armis is its excellent knowledge base, which contains critical information about the billions of devices under its monitoring umbrella, including both the device profile and the expected behaviors of that device,” said Chris Ray, Research Analyst at GigaOm. “This solution is able to leverage that information to quickly identify unusual or abnormal conditions that legacy security tools (like an intrusion detection system, or IDS) would not be able to detect. Armis has a strong focus on healthcare, manufacturing and the public sector. From our point of view, the product complements existing OT security solutions.”
“From an overall security perspective, visibility into the manufacturing area was a big thing for us,” said Shem Stephens, Security Engineer at Colgate-Palmolive. “We needed a tool to see what our plants are doing in order to better support them in terms of their security posture— and Armis fit the bill perfectly. Our auditing team uses Armis to look into areas of opportunity at our plants. And systems engineers use Armis to see when a programmable logic controller (PLC) was last changed out. They have that information at their fingertips now. As our leadership continues to collaborate with Armis leadership, we can create these unique use cases that provide tremendous benefits for specific teams or individuals.”
To read the full GigaOm Radar Report for Operational Technology (OT) Security, please visit: https://www.armis.com/analyst-reports/gigaom-radar-for-ot-security/
For the Armis blog surrounding this report, go to: https://www.armis.com/blog/armis-named-leader-in-gigaom-radar-report-for-operational-technology-ot-security/
Learn more about Armis’ OT cybersecurity solutions and how the company is helping customers secure operational technology here: https://www.armis.com/solutions/ot-device-security/
About Armis
Armis, the leading asset visibility and security company, provides the industry’s first unified asset intelligence platform designed to address the new extended attack surface that connected assets create. Fortune 100 companies trust our real-time and continuous protection to see with full context all managed, unmanaged assets across IT, cloud, IoT devices, medical devices (IoMT), operational technology (OT), industrial control systems (ICS), and 5G. Armis provides passive cyber asset management, risk management, and automated enforcement. Armis is a privately held company and headquartered in California.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230710189829/en/
Contact information
Media Contacts:
Rebecca Cradick
Senior Director, Global Communications
Armis
pr@armis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 15:00:00 EET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
